6760 Journal of Medicinal Chemistry, 2005, Vol. 48, No. 21
Brief Articles
crystals, yield 34%; mp 168-170 °C; 1H NMR (CDCl3) δ: 2.41
J.; Castro, J. L.; Ragan, C. I.; Dawson, G. R.; Whiting, P. J.
Sedative but not anxiolytic properties of benzodiazepines are
mediated by the GABAA receptor Rl subtype. Nat. Neurosci.
2000, 3, 587-592. (b) Rudolph, U.; Crestani, F.; Mo¨hler, H.
GABAA receptor subtypes: dissecting their pharmacological
functions. Trends Pharmacol. Sci. 2001, 22, 188-194.
(7) Kralic, J. E.; O’Buckley, T. K.; Khisti, R. T.; Hodge, C. W.;
Homanics, G. E.; Morrow, A. L. GABAA receptor R1 subunit
deletion alters receptor subtype assembly, pharmacological and
behavioural responses to benzodiazepines and Zolpidem. Neu-
ropharmacology 2002, 43, 685-694.
(s, 3H, p-CH3), 2.58 (s, 3H, 5-CH3), 3.01 (s, 3H, N(CH3)2), 3.17
(s, 3H, N(CH3)2), 3.93 (s, 2H, CH2), 6.63 (d, 1H, H-6, JH6-H7
)
7.0 Hz,), 7.30 (d, 2H, Ph), 7.67 (d, 2H, Ph), 8.50 (d, 1H, H-7,
JH7-H6 ) 7.0 Hz). Anal. (C18H20N4O) C, H, N.
Acknowledgment. This research was supported by
funds of the Italian Ministry of University and Scientific
Research (MURST).
(8) Selleri, S.; Bruni, F.; Costagli, C.; Costanzo, A.; Guerrini, G.;
Ciciani, G.; Gratteri, P.; Bonaccini, C.; Malmberg Aiello P.;
Besnard, F.; Renard, S.; Costa, B.; Martini, C. J. Med. Chem.
2003, 46, 310-313.
(9) Chimichi, S.; Cosimelli, B.; Bruni, F.; Selleri, S. Can. J. Chem.
1992, 70, 1093-1097.
(10) Dawson, G. R.; Tricklebank, M. D. Use of the elevated plus maze
in the search for novel anxiolytic agents. Trends Pharmacol. Sci.
1995, 16, 33-36.
(11) (a) Dar, M. S. Modulation of ethanol-induced motor incoordina-
tion by mouse striatal A1 adenosinergic receptor. Brain. Res.
Bull. 2001, 55, 1331-1335. (b) Lelas, S.; Rowlett, J. K.; Speal-
man, R. D.; Cook, J. M.; Ma, C.; Li, X.; Yin, W. Role of GABAA/
benzodiazepine receptors containing R1 and R5 subunits in the
discriminative stimulus effects of triazolam in squirrel monkeys.
Psychopharmacology 2002, 161, 180-188.
Supporting Information Available: Elemental analyses
data, binding studies, and pharmacological methods. This
material is available free of charge via the Internet at: http://
pubs.acs.org.
References
(1) (a) Sieghart, W.; Sperk, G. Subunit Composition, Distribution
and Function of GABAA Receptor Subtypes. Curr. Top. Med.
Chem. 2002, 2, 795-816. (b) Mohler H.; Fritschy, J. -M.;
Crestani, F.; Hensch, T.; Rudolph, U. Specific GABAA circuits
in brain development and therapy. Biochem. Pharmacol. 2004,
68, 1685-1690.
(2) Paronis, C. A.; Cox, E. D.; Cook, J. M.; Bergman, J. Different
types of GABAA receptors may mediate the anticonflict and
response rate-decreasing effects of Zaleplon, Zolpidem and
Midazolam in squirrel monkeys. Psychopharmacology 2001, 156,
461-468.
(3) Basile, A. S.; Lippa, A. S.; Skolnick, P. Anxioselective anxiolyt-
ics: can less be more? Eur. J. Pharmacol. 2004, 500, 441-451.
(4) Belzung, C.; Le Guisquet, A. M.; Griebel, G. â-CCT, a selective
BZ-ω1 receptor antagonist, blocks the anti-anxiety but not the
amnesic action of chlordiazepoxide in mice. Behav. Pharmacol.
2000, 11, 125-131.
(5) (a) Shannon, H. E.; Guzman, F.; Cook, J. M. â-carboline-3-
carboxylate-tert-butyl ester: A selective BZ1 benzodiazepine
receptor antagonist. Life Sci. 1984, 35, 2227-2236. (b) Takada,
K.; Hagen, T. J.; Cook, J. M.; Goldberg, S. R. Katz, J. L.
Discriminative stimulus effects of intravenous nicotine in squir-
rel monkeys. Pharmacol. Biochem. Behav. 1988, 30, 243-247.
(c) Rowlett, J. K.; Tornatzky, W.; Cook, J. M.; Ma, C.; Miczek,
K. A. Zolpidem, triazolam, and diazepam decrease distress
vocalizations in mouse pups: differential antagonism by fluma-
zenil and â-Carboline-3-carboxylate-tert-butyl ester (â-CCt). J.
Pharmacol. Exp. Ther. 2001, 297, 247-253.
(12) Balkin, T. J.; O’Donnel, V. M.; Wesensten, N.; McCann, U.;
Belenky, G. Comparison of the daytime sleep and performance
effects of Zolpidem versus triazolam. Psychopharmacology 1992,
107, 83-88.
(13) (a) Bailey, D. J.; Tetzlaff, J. E.; Cook, J. M.; He, X.; Helmstetter,
F. J. Effects of Hippocampal Injection of a Novel Ligand Selective
for the R5â2γ2 Subunits of the GABA/Benzodiazepine Receptor
on Pavlovian Conditioning. Neurobiol. Learn. Mem. 2002, 78,
1-10. (b) Chambers, M. S.; Atack, J. R.; Broughton, H. B.;
Collinson, N.; Cook, S.; Dawson, G. R.; Hobbs, S. C.; Marshall,
G.; Maubach, K. A.; Pillai, G. V.; Reeve, A. J.; MacLeod, A. M.
Identification of a Novel, Selective GABAA R5 Receptor Inverse
Agonist Which Enhances Cognition. J. Med. Chem. 2003, 46,
2227-2240. (c) De Lorey, T. M.; Lin, R. C.; McBrady, B.; He, X.;
Cook, J. M.; Lameh, J.; Loew, G. H. Influence of benzodiazepine
binding site ligands an fear-conditioned contextual memory. Eur.
J. Pharmacol. 2001, 426, 45-54.
(14) Seneci, P.; Nicola, M.; Inglesi, M.; Vanotti, E.; Resnati, G.
Synthesis of mono-, disubstituted 1H-imidazo[1,2-b]pyrazole.
Synth. Commun. 1999, 29, 311-342.
(6) (a) McKernan, R. M.; Rosahl, T. W.; Reynolds, D. S.; Sur, C.;
Wafford, K. A.; Atack, J. R.; Farrar, S.; Myers, J.; Cook, G.;
Ferris, P.; Garret, L.; Bristow, L.; Marshall, G.; Macaulay, A.;
Brown, N.; Howell, O.; Moore, K. W.; Carling, R. W.; Street, L.
JM058002N